The enigma of ectopic expression of FGFR3 in multiple myeloma: A critical initiating event or just a target for mutational activation during tumor progression

Current Opinion in Hematology

Volumn 9, Issue 4, 2002, Pages 288-293

  Chesi, Marta ^a   Bergsagel, P Leif ^a   Kuehl, W Michael ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 3; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; STAT1 PROTEIN; STAT3 PROTEIN; FGFR3 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL MODEL; CARCINOGENESIS; CELL STRAIN 3T3; CHROMOSOME 14; CHROMOSOME 4; CHROMOSOME TRANSLOCATION; ENZYME ACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HEMATOPOIESIS; MONOCLONAL IMMUNOGLOBULINEMIA; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PATHOGENESIS; PLASMA CELL; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ANIMAL; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; HUMAN; METABOLISM; MUTATION; PATHOLOGY;

ANIMAL; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN; MULTIPLE MYELOMA; MUTATION; RECEPTORS, FIBROBLAST GROWTH FACTOR; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSLOCATION (GENETICS); ANIMALS; HUMANS; PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; TRANSLOCATION, GENETIC;

EID: 0036014969     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200207000-00005     Document Type: Review

References (34)

1. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3
2. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma
3. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance
4. Detection of t(4;14)(pt 6.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts
5. Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis
6. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts
7. A novel chromosomal translocation t(4;14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene
8. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: The achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans
9. FGFR activation in skeletal disorders: Too much of a good thing
10. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma
11. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)
12. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): Comparative analysis of Y373C, K650E and the novel G384D mutations
13. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: Analysis of the Eastern Cooperative Oncology Group Phase III Trial
14. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis
15. The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells
16. Update of gp 130 cytokines in multiple myeloma
17. Interleukin-6 is a growth factor for nonmalignant human plasmablasts
18. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade
19. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells
20. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
21. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: Roles in cytokine-dependent survival and proliferative responses
22. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
23. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis
24. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6
25. p53 and RAS gene mutations in multiple myeloma
26. Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2)
27. Chromosome translocations in multiple myeloma
28. 8p12 stem cell myeloproliferative disorder: The FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways
29. ZNF198-FGFR1 transforming activity depends on a novel proline-rich ZNF198 oligomerization domain
30. Basic fibroblast growth factor and hematopoiesis
31. Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1
32. Interphase detection of t(4;14)(p16.3;q32.3) by in situ hybridization and FGFR3 overexpression in plasma cell malignancies
33. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization
34. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins